OpenAlex
PricingAboutJobs
Log inGet started
Work

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

HTML

Year: 2025
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet
DOI: 10.1016/s0140-6736(25)01185-7
Authors: Kirsten Dahl, Søren Toubro, Sohan Dey, Ruben Duque do Vale, Anne Flint, Agnes Gasiorek, Arne Heydorn, Ania M Jastreboff, Cassandra Key, Signe Beck Petersen, Andreas Vegge, Kasper Adelborg
Institutions: Novo Nordisk (Denmark), Novo Nordisk (India), Yale University
Language: English

Topic: Pharmacology and Obesity Treatment
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Keywords: GLP-1 receptor agonists, amylin receptor agonist, obesity, overweight, weight loss, subcutaneous administration, pharmacokinetics, safety and tolerability, treatment-emergent adverse events, gastrointestinal adverse effects, dose escalation, weight change, single ascending dose, multiple ascending dose, GLP-1 receptor, amylin
SDG: Good health and well-being

Open Access status: closed

Funders: Novo Nordisk, Apollo
OpenAlex ID: W4411475014
FWCI: 33.07
Cites: 31
Cited by: 95
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security